Welcome to our dedicated page for Inspira Tech news (Ticker: IINNW), a resource for investors and traders seeking the latest updates and insights on Inspira Tech stock.
Inspira Technologies Oxy B.H.N. Ltd. reports developments in life-support and respiratory treatment technologies for critical care patients. Company news commonly covers the INSPIRA™ ART100 system, an FDA-cleared cardiopulmonary bypass system that adds oxygen to blood and removes carbon dioxide before returning blood to the patient, as well as product features for clinical workflow, alarm management and emergency uptime.
Recurring updates also address U.S. deployment activity, medical-device production arrangements, VORTX™ blood oxygenation delivery technology, the HYLA™ blood sensor, Israeli AMAR certification for extracorporeal membrane oxygenation and cardiopulmonary bypass procedures, and board-level governance changes.
Inspira Technologies has announced the first-in-human use of its HYLA Blood sensor during open-heart surgery at Sheba Medical Center in Israel. This non-invasive sensor utilizes machine learning to measure key blood parameters in real-time, aiming to enhance patient care during procedures like VV-ECMO and VA-ECMO. The ongoing HYLA clinical study compares the sensor's performance against traditional blood gas analyzers. The company's advanced Augmented Respiration Technology (INSPIRA ART) seeks to improve oxygen saturation levels without invasive ventilation methods. Regulatory approval is still pending for these technologies.
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) has received Ethics Committee approval from Sheba Medical Center in Israel to conduct a clinical study of the HYLA blood sensor. This non-invasive device aims to measure blood parameters during open-heart surgery, providing real-time alerts for patient condition changes. The study is set to begin in Q1 2023 and seeks to compare HYLA sensor measurements with standard blood gas analyzers. This development may enhance patient monitoring and reduce complications in cardiac care.
Inspira Technologies has received a patent from the U.S. Patent and Trademark Office for its innovative convertible dual lumen cannula device, crucial for its INSPIRA ART System. The patent encompasses 20 claims deemed novel, emphasizing its inventive step and industrial applicability. The device allows intravascular conversion of a single-lumen cannula into a dual lumen one, enhancing usability during medical procedures like ECMO. The company plans to seek international patents, integrate this device with existing products, and consider its separate commercialization as a disposable item, aiming to improve patient safety and procedural efficiency.
Inspira Technologies will be featured on The RedChip Money Report on Bloomberg TV on December 24, 2022. Co-Founder Joe Hayon discusses Inspira's innovative respiratory support technology aimed at reducing reliance on invasive mechanical ventilation. The interview highlights plans to initiate human studies and the potential of Inspira's technology to become the new standard of care for acute respiratory failure. The company's products are still in development and have not been tested on humans.
Inspira Technologies (NASDAQ:IINN, IINNW) will be featured in an interview on The RedChip Money Report airing on Bloomberg TV on October 22, 2022, at 7 p.m. ET. During the interview, President Joe Hayon will discuss the Company's InspiraART System and HYLA blood sensor, highlighting significant market opportunities and their product pipeline. The InspiraART technology aims to improve patient oxygen saturation while reducing reliance on invasive mechanical ventilation. The technology is yet to be tested in humans and is pending regulatory approval.
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, NASDAQ:IINNW) will be featured on The RedChip Money Report airing on Bloomberg TV on July 2, 2022, at 7 p.m. ET. CEO Dave Gentry interviews CFO Joe Hayon, discussing the Company’s Augmented Respiration Technology (ART), which aims to enhance respiratory support for acute respiratory failure patients. The technology seeks to minimize the need for invasive ventilation methods. Inspira targets $401 million in potential sales through its ongoing agreements and is actively pursuing regulatory approval in the U.S. and Europe.
Aegis Capital Corp. acted as Sole Bookrunner for a $16.0 million Initial Public Offering of Common Units for Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN, IINNW). The company is focused on respiratory treatments with its innovative Augmented Respiration Technology that stabilizes oxygen saturation levels, allowing patients to remain awake during treatment.
This technology aims to reduce reliance on mechanical ventilation, which is often invasive and risky.